PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells

Landmark research project is 100x larger than existing efforts and will use cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments

Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells
2023-06-01
(Press-News.org)

– Cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments –

– Landmark research project is 100x larger than existing efforts – 

– Data will be generated from thousands of patients across multiple cancers –

– University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander-Universität Erlangen-Nürnberg , Charité - Universitätsmedizin Berlin join Owkin, NanoString and other experts in high throughput tissue mapping technologies to discover novel cancer treatments –

Paris and Seattle, June 1, 2023-- Owkin, Nanostring (NASDAQ:NSTG), and world-leading cancer research institutions University of Pittsburgh, Gustave Roussy, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, and Charité - Universitätsmedizin Berlin are launching MOSAIC (Multi Omic Spatial Atlas In Cancer) at the American Society of Clinical Oncology’s annual meeting (booth #4037). MOSAIC is a landmark $50 million project to revolutionize cancer research through the use of spatial omics, a set of cutting-edge technologies that offer unprecedented information on the structure of tumors.

Spatial omics allows researchers to examine tumors at a near single-cell resolution, while revealing the location and molecular activity of tumor and immune cells. It provides a detailed map of molecular interactions, allowing scientists to decipher key relationships between a tumor and its environment. By generating and analyzing unprecedented amounts of spatial omics data in combination with multimodal patient data and artificial intelligence, MOSAIC aims to unlock the next wave of treatments for some of the most difficult-to-treat cancers.

The first initiative of its kind using spatial omics technology, MOSAIC holds the potential to open a new field in oncology treatment research. Collaborating with Gustave Roussy, the University of Pittsburgh through the UPMC Hillman Cancer Center, Lausanne University Hospital, Uniklinikum Erlangen/Friedrich-Alexander- Universität Erlangen-Nürnberg, Charité - Universitätsmedizin Berlin, NanoString Technologies and other providers of analytical instrumentation and assays for spatial biology, Owkin will invest $50 million to build MOSAIC. It will use 7,000 tumor samples from patients, making it over 100 times larger than any existing spatial omics datasets. Owkin and the MOSAIC partners will mine this resource for immune-oncology disease subtypes in pursuit of biomarkers and novel therapies.

Thomas Clozel, Co-founder, and CEO of Owkin, said:

“The convergence of spatial omics, multimodal patient data, and AI will power the next revolution in oncology research, unlocking the next wave of breakthrough treatments for patients. MOSAIC will help us, and our partners make unprecedented breakthroughs in the fight against cancer.”

Brad Gray, President & CEO of NanoString, said,

“This project holds potential to transform our understanding of cancer biology and spark the development of novel diagnostics and therapeutics. It is an unprecedented collaboration, bringing together NanoString’s powerful spatial biology platforms, the highest quality clinically annotated cancer samples from top cancer research centers, and Owkin’s extraordinary A.I. technology and analytics. “

Robert Ferris, MD, PhD, Associate Vice Chancellor for Cancer Research and Hillman Professor of Oncology at the University of Pittsburgh School of Medicine and Director of UPMC Hillman Cancer Center, said:

“The University of Pittsburgh is excited to be a part of the MOSAIC consortia, which will leverage our UPMC Hillman Cancer Center spatial-omic expertise in understanding cancer cells in their environment. We are enthusiastic to work with other universities and industry partners to uncover actionable insights to detect, treat, and prevent cancer.”

Professor Fabrice André, Director of Research and Professor of Medical Oncology at Gustave Roussy, Paris, said:

“With MOSAIC that combines the most advanced technologies, we are entering a new dimension for the understanding of the mechanism and interaction of tumor cells and their micro-environment. This exciting project will help us discover new therapeutic treatments for patients. Few centers in the world are involved in a project of such magnitude.”

Professor Mauro Oddo, Director of Innovation and Clinical Research at the Lausanne University Hospital, said:

“The MOSAIC project introduces cutting-edge healthcare technology with great potential to advance cancer prediction and treatment. It is also a demonstration of how scientific partnerships between leading academic hospitals and biotech companies are instrumental for successfully translating innovation into improved patient care. It is therefore a great opportunity for the CHUV, in particular through its Biomedical Data Science Center and the Divisions of Medical Oncology and Pathology, to be part of the MOSAIC project.”

Prof. Dr. Arndt Hartmann, Head of the Institute of Pathology of Uniklinikum Erlangen, said:

“The comprehensive characterization of large patient cohorts of cancers with poor prognosis and high medical need for new therapies using spatial omics will provide unprecedented knowledge about tumors and tumor microenvironment. The consortium of large cancer centers with strong commercial partners provides the unique opportunity to detect new treatment options for our patients.”

Prof. Dr. Ulrich Keilholz, Professor of Comprehensive Oncology, Director of Charité Comprehensive Cancer Center, said:

“The Owkin MOSAIC study is a milestone project for us and an exciting opportunity to significantly broaden our single cell multi-omics expertise and achieve an understanding of many cancers at a very detailed level.”

What is spatial omics?

Spatially resolved molecular profiling (also known as spatial omics), recognized as Method of the Year by Nature Methods, is an advanced group of technologies for quantifying and localizing molecular expression that offers scientists an unparalleled view of tumor structures at near single-cell resolution, revealing interactions between tumor and non-tumor cells. By measuring a molecule's expression and mapping it back to its location within the tumor sample, spatial omics allows researchers to 'zoom in' on tumor heterogeneity, cell-cell communication, and tumor-immune system interactions. This innovative approach is set to catalyze unprecedented scientific breakthroughs and transform our fundamental understanding of disease mechanisms.

How will MOSAIC work?

Following the analysis of patient data from research centers using NanoString's spatial omics technology, combined with RNA-seq, proteomics, histology and other medical data, Owkin will develop a data platform and employ its machine learning expertise, including deep neural networks, to uncover novel cancer biology and potential therapies. 

MOSAIC will initially focus on multiple cancers with unmet medical needs, including non-small cell lung cancer, triple-negative breast cancer, diffuse large B cell lymphoma, ovarian cancer, glioblastoma, mesothelioma, and bladder cancer. After an initial research period, MOSAIC and its standardized data generation and analysis methods will be made accessible to the global biomedical community, further propelling advancements in oncology research.

What is the significance of MOSAIC?

By utilizing spatial omics technology and AI, MOSAIC enables researchers to examine cancer tumors at nearly single-cell resolution, providing unprecedented insights into the structure, molecular interactions, and cell-to-cell communication within tumors. This detailed information can help scientists better understand complex biological processes and develop more targeted and effective treatments for challenging cancers.

MOSAIC's scale significantly surpasses existing spatial omics studies. Previous efforts are too small by two orders of magnitude to drive breakthroughs. Presently, most studies involving these data modalities are constrained by sample sizes, typically fewer than 50. In contrast, MOSAIC will analyze data from 7,000 patients, enabling scientists to conduct research on data cohorts that are 100 times larger than currently possible.

Who is involved in MOSAIC?

MOSAIC is led by AI biotech company Owkin, providing foundational expertise in artificial intelligence, data science and oncology. NanoString is providing MOSAIC with a world-leading technological foundation for biomarker discovery and translational research, including through the use of NanoString’s GeoMx® Digital Spatial Profiler and CosMx™ Spatial Molecular Imager platforms. Academic research partners will provide their expertise to manage the scientific conduct of the study and conduct research on the MOSAIC data.

About Owkin 

Owkin is an AI biotechnology company that uses AI to find the right treatment for every patient. We combine the best of human and artificial intelligence to answer the research questions shared by biopharma and academic researchers. By closing the translational gap between complex biology and new treatments, we bring new diagnostics and drugs to patients sooner.

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools. Using federated learning, a pioneering collaborative AI framework, Owkin enables partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-hematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma companies (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).

About NanoString Technologies, Inc

NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology. The GeoMx® Digital Spatial Profiler, cited in approximately 230 peer-reviewed publications, is a flexible and consistent solution combining the power of whole tissue imaging with gene expression and protein data for spatial whole transcriptomics and proteomics from one FFPE slide. The CosMx™ Spatial Molecular Imager is an FFPE-compatible, single-cell imaging platform powered by spatial multi omics enabling researchers to map single cells in their native environments to extract deep biological insights and novel discoveries from one experiment. The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere. At the foundation of our research tools is our nCounter® Analysis System, cited in approximately 7,000 peer-reviewed publications, which offers a secure way to easily profile the expression of hundreds of genes, proteins, miRNAs, or copy number variations, simultaneously with high sensitivity and precision.

About Gustave Roussy 

Ranked as the leading European Cancer Centre and third in the world, Gustave Roussy is a center with comprehensive expertise and is devoted entirely to patients suffering with cancer. The Institute is a founding member of the Paris-Saclay Cancer Cluster. It is a source of diagnostic and therapeutic advances. It caters for almost 50,000 patients per year and its approach is one that integrates research, patient care and teaching. It is specialized in the treatment of rare cancers and complex tumors and it treats all cancers in patients of any age. Its care is personalized and combines the most advanced medical methods with an appreciation of the patient’s human requirements. In addition to the quality of treatment offered, the physical, psychological and social aspects of the patient’s life are respected. 4,100 professionals work on its two campuses: Villejuif and Chevilly-Larue. Gustave Roussy brings together the skills, which are essential for the highest quality research in oncology: 40% of patients treated are included in clinical trials.  

About the Lausanne University Hospital (CHUV)

The CHUV plays a leading role in the fields of medical care, research, teaching, and training, in collaboration with the Faculty of Biology and Medicine at the University of Lausanne (UNIL). Both these institutions are part of the "Health Valley" around Leman Lake. With its mission lying at the crossroads between medicine, sciences, and humanities, CHUV offers a personalized approach to patient care. Several national and international collaborations allow us to deliver the best possible care to our patients.The Division of Medical Oncology within the Department of Oncology UNIL CHUV is the largest in Switzerland with more than 45’000 consultations/year. In addition, the Experimental Therapeutic Center (CTE) runs more than 100 clinical trials. The Department of Oncology is part of the Ludwig Institute for Cancer Research (LICR) and highly active in the field of Immune Oncology and Cellular therapy at the preclinical, translational, and clinical level.Thanks to its role as European reference center in oncology, CHUV is a key partner for MOSAIC, contributing with its broad know-how on biomarkers identification in immunotherapy, tumor microenvironment analysis, and cancer genomics.

About Erlangen 

The Institute of Pathology of Uniklinikum Erlangen (UKER) is a high-throughput provider of classical diagnostic pathology and has a broad expertise in conventional surgical pathology, IHC, molecular pathology and digital pathology with 11 specialists, 9 physicians in training and more than 40 additional scientific staff. The expertise is used in diagnostics as well as in research. The MOSAIC UKER PIs, Prof. Dr. Arndt Hartmann, Dr. Markus Eckstein and PD Dr. Ramona Erber, are experts in the field of cancer research with subspecialties in genitourinary pathology, breast pathology, gynaecopathology and immunopathology. Moreover, the Institute of Pathology of Uniklinikum Erlangen is the central pathology institute of several (immune-)oncological clinical trials. Uniklinikum Erlangen is a partner in the Comprehensive Cancer Center Erlangen-EMN and the National Center for Tumor Diseases (NCT WERA).

About Charité - Universitätsmedizin Berlin

The Charité is the medical faculty of the Humboldt University and the Free University of Berlin. With more than 3000 inpatient beds in three full University hospital sites within the city of Berlin, Germany, the Charité is one of the largest University Medical Centers in Europe. In international comparisons, the Charité usually ranks among the top ten global institutions. Key focus areas include oncology, inflammation, cardiovascular diseases, neuroscience, and rare diseases. The Charité Comprehensive Cancer Center (CCCC) is the largest cancer center of Germany and carries the responsibility for seamless interdisciplinary patient care and cancer research of all Charité departments.  One focus area is comprehensive precision oncology, encompassing early clinical trials with signal transduction inhibitors and various forms of cancer immunotherapy. The CCCC closely collaborates with Berlin research institutions as well as national and international networks. Among several research areas, a stronghold includes single cell multi-omics technologies and data sciences.

END


[Attachments] See images for this press release:
Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells 2

ELSE PRESS RELEASES FROM THIS DATE:

Adolescents are aware of and invested in the potential impacts of abortion restrictions, study says

Adolescents are aware of and invested in the potential impacts of abortion restrictions, study says
2023-06-01
CHAPEL HILL, N.C. – On July 1, North Carolina’s new abortion limits go into effect. As restrictions on abortions are being tightened across the United States, adolescents may encounter mounting obstacles that could prevent them from accessing abortion care. Bianca A. Allison, MD MPH, an assistant professor in the Department of Pediatrics, sought to examine the awareness and knowledge that adolescents have about the legal landscape of abortion and how these changes might affect them and their communities. The study, published in the Journal of Adolescent Health, found that many adolescents – across a diversity of ...

Family resemblance: How T cells could fight many coronaviruses at once

Family resemblance: How T cells could fight many coronaviruses at once
2023-06-01
LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) are investigating how the immune system's T cells react to a wide variety of coronaviruses, ranging from SARS to common cold coronaviruses. Their goal is to guide the development of vaccines that could halt future pandemic by combatting many types of coronaviruses at once.   "While it was recognized that coronaviruses were potentially dangerous viruses, because of SARSCoV and MERS viruses causing very severe disease in humans, nobody knew that the next pandemic was going to be caused by SARS-CoV-2," says LJI Professor Alessandro Sette, Dr.Biol.Sci. ...

New UNC study quantifies disparity among minority communities exposed to traffic-related air pollution across the U.S.

2023-06-01
Traffic-related air pollution is a pervasive problem across the United States. Vehicle emissions are highest near major roadways with around 19% of the U.S. population living in the vicinity of a major roadway. In more densely populated states, like California, up to 40% live near a major roadway. Exposure to these pollutants, such as fine particulate matter (PM2.5 ) and nitrogen dioxide (NO2), a byproduct of burning fossil fuel, can lead to a host of health effects including premature death. Minority communities often live along these corridors and experience disproportionate exposures. A ...

Study identifies boat strikes as a growing cause of manatee deaths in Belize

Study identifies boat strikes as a growing cause of manatee deaths in Belize
2023-06-01
The endangered Antillean manatee faces a growing threat from boat strikes in Belize, according to a new study that raises concerns about the survival of what had been considered a relatively healthy population. Belize hosts a population of around 1,000 manatees. With the growth of tourism in recent decades, however, Belize has seen a substantial increase in boat traffic, making boat strikes an increasingly important cause of manatee deaths and injuries. The new study, published June 1 in Endangered Species Research, used 25 years of data on manatee strandings (dead or injured ...

Biologists to create ‘toolbox’ for understanding complex genetic traits

Biologists to create ‘toolbox’ for understanding complex genetic traits
2023-06-01
Driven by a lifelong curiosity about the natural world and the diversity of life, Elizabeth King, associate professor in the Division of Biological Sciences at the University of Missouri, found inspiration to spend her formative years studying science — and along the way she discovered her passion for biology. That foundation has led her to pursue an ongoing career working to develop a better understanding of genetic traits from a biological perspective. Recently, the National Institutes of Health (NIH) awarded King a five-year, $1.9 million grant to expand her lab’s research ...

Salton Sea environment detrimental to respiratory health of local children

Salton Sea environment detrimental to respiratory health of local children
2023-06-01
RIVERSIDE, Calif. -- In the United States, low-income immigrant and minority children often live in environments that have highly polluted air. A study led by researchers at the University of California, Riverside, demonstrates this among the Latinx and Purépecha immigrant children and caregivers living along Inland Southern California’s Salton Sea, a highly saline drying lakebed surrounded by agricultural fields. The Purépecha community is an Indigenous group from the Mexican state of Michoacán. “Children of Latinx ...

Fellowship offers reporters valuable insight as America ages

2023-06-01
The Gerontological Society of America (GSA) has received renewed grant support to welcome a new class of reporters for the Journalists in Aging Fellows Program. The 2023 funders to date include Silver Century Foundation, The John A. Hartford Foundation, Archstone Foundation, and NIHCM Foundation. Since its founding in 2010, this program has been responsible for more than 800 news stories produced by 217 alumni. It has two goals: to educate journalists about issues in aging, better allowing them to spread a new awareness to general-audience, ethnic, and other minority populations; ...

Critical decision-3A clears way toward standard model test

Critical decision-3A clears way toward standard model test
2023-06-01
NEWPORT NEWS, VA – The U.S. Department of Energy has given the greenlight for the MOLLER experiment to begin procurement of key components with its granting of Critical Decision-3A (CD-3A): Approve Long Lead Procurements. The determination allows the MOLLER project at DOE’s Thomas Jefferson National Accelerator Facility to begin spending $9.14 million for long-lead procurements of critical items for which designs are complete. After imagining what it would look like for 17 years, Krishna Kumar felt chills the first time he saw fully engineered drawings of the MOLLER experiment.  “Seeing the designs on paper gave me pins and needles,” said Kumar, professor of ...

Sandia scientists achieve breakthrough in tackling PFAS contamination

Sandia scientists achieve breakthrough in tackling PFAS contamination
2023-06-01
ALBUQUERQUE, N.M. — A team at Sandia National Laboratories is developing materials to tackle what has become one of the biggest problems in the world: human exposure to a group of chemicals known as PFAS through contaminated water and other products. Sandia is now investing more money to take their research to the next level. “It’s in the news constantly. It seems every day we hear of another product that is contaminated. We saw sparkling water with PFAS, toilet paper with PFAS, so it’s ...

Better search for the cause of hereditary diseases

2023-06-01
So far, it has not been possible to explain the causes of around half of all rare hereditary diseases. A Munich research team has developed an algorithm that predicts the effects of genetic mutations on RNA formation six times more precisely than previous models. As a result, the genetic causes of rare hereditary diseases and cancer can be identified more precisely. Variations of genetic sequence occur relatively frequently – on average, one in a thousand nucleotide of a person’s genome is affected. In rare cases, these changes can lead to defective RNAs and hence non-functional proteins. This can lead to dysfunction in individual organs. If a rare disease is suspected, computer-assisted ...

LAST 30 PRESS RELEASES:

Modesty and boastfulness – perception depends on usual performance

Do sweeteners increase your appetite? New evidence from randomised controlled trial says no 

Women with obesity do not need to gain weight during pregnancy, new study suggests

Individuals with multiple sclerosis face substantially greater risk of hospitalisation and death from COVID-19, despite high rates of vaccination

Study shows obesity in childhood associated with a more than doubling of risk of developing multiple sclerosis in early adulthood

Rice Emerging Scholars Program receives $2.5M NSF grant to boost STEM education

Virtual rehabilitation provides benefits for stroke recovery

Generative AI develops potential new drugs for antibiotic-resistant bacteria

Biofuels could help island nations survive a global catastrophe, study suggests

NJIT research team discovering how fluids behave in nanopores with NSF grant

New study shows association of historical housing discrimination and shortfalls in colon cancer treatment

Social media use may help to empower plastic surgery patients

Q&A: How to train AI when you don't have enough data

Wayne State University researchers uncover potential treatment targets for Zika virus-related eye abnormalities

Discovering Van Gogh in the wild: scientists unveil a new gecko species

Small birds spice up the already diverse diet of spotted hyenas in Namibia

Imaging detects transient “hypoxic pockets” in the mouse brain

Dissolved organic matter could be used to track and improve the health of freshwaters

Indoor air quality standards in public buildings would boost health and economy, say international experts

Positive associations between premenstrual disorders and perinatal depression

New imaging method illuminates oxygen's journey in the brain

Researchers discover key gene for toxic alkaloid in barley

New approach to monitoring freshwater quality can identify sources of pollution, and predict their effects

Bidirectional link between premenstrual disorders and perinatal depression

Cell division quality control ‘stopwatch’ uncovered

Vaccine protects cattle from bovine tuberculosis, may eliminate disease

Andrew Siemion to receive the SETI Institute’s 2024 Drake Award

New study shows how the Crimean-Congo hemorrhagic fever virus enters our cells

Neoadjuvant chemotherapy proves effective for locally advanced penile squamous cell carcinoma

Study flips treatment paradigm in bilateral Wilms tumor, shows resistance to chemotherapy may point toward favorable outcomes

[Press-News.org] Owkin powers a new era in oncology research with MOSAIC – an unprecedented $50 million spatial atlas of cancer cells
Landmark research project is 100x larger than existing efforts and will use cutting-edge spatial omics technologies to map cancer cells and their immune environment in high resolution, allowing AI to unlock potential for new breakthrough treatments